Skip to main content
FIREBRICK PHARMA LIMITED logo

FIREBRICK PHARMA LIMITED — Investor Relations & Filings

Ticker · FRE ISIN · AU0000197352 ASX Manufacturing
Filings indexed 293 across all filing types
Latest filing 2026-05-21 Proxy Solicitation & In…
Country AU Australia
Listing ASX FRE

About FIREBRICK PHARMA LIMITED

https://firebrickpharma.com/

Firebrick Pharma Limited is a pharmaceutical company focused on developing and commercializing innovative therapies for respiratory viral infections. The company's primary asset is Nasodine® Nasal Spray, a broad-spectrum antiseptic formulation containing povidone-iodine (PVP-I). Nasodine is designed to target the nasal passages, the primary site where respiratory viruses, including those causing the common cold, replicate. By utilizing the established antimicrobial properties of PVP-I, the product aims to reduce viral load and alleviate symptoms at the source of infection. Firebrick Pharma's research and development efforts center on clinical validation and regulatory pathways to establish Nasodine as a first-in-class treatment for viral upper respiratory tract infections. The company focuses on addressing unmet needs in the management of the common cold through evidence-based antiseptic interventions.

Recent filings

Filing Released Lang Actions
Notice of GM & Proxy Form & Access Letter 23 pages 604.6KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of General Meeting including resolutions to be voted on, proxy forms, voting instructions, and an Explanatory Statement. It is sent to shareholders to provide information about the meeting and solicit their votes. It does not contain financial statements or audit data, nor is it announcing results. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2026-05-21 English
Change of Director's Interest Notice - Stephen Goodall 3 pages 304.7KB
Director's Dealing Classification · 98% confidence The document is an ASX Appendix 3Y "Change of Director's Interest Notice" reporting a director’s security holdings, acquisitions and disposals under Corporations Act and Listing Rules. It is a mandatory insider trading report by a director. This clearly falls under Director’s Dealing (insider trades).
2026-05-20 English
Change of Director's Interest Notice - Peter Molloy 3 pages 329.5KB
Director's Dealing Classification · 90% confidence The document is an ASX Appendix 3Y “Change of Director’s Interest Notice,” detailing a director’s personal share transactions under Listing Rule 3.19A. It discloses the nature, number, and value of securities acquired, which matches the definition of a Director’s Dealing report (insider trades).
2026-05-20 English
Application for quotation of securities - FRE 6 pages 18.4KB
Share Issue/Capital Change Classification · 91% confidence The document is an ASX Appendix 2A “Application for quotation of securities,” detailing the issue and quotation of 225,000 new ordinary shares following options conversion. This is a direct announcement of a new share issuance and capital change under ASX rules. As such, it fits the 'Share Issue/Capital Change' category (Code: SHA).
2026-05-20 English
Cleansing Notice 2 pages 135.0KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX release titled 'Notice under Section 708A of the Corporations Act' describing the issuance of 225,000 ordinary shares upon exercise of options. This is a formal announcement of a new share issue/capital change. It does not present financial statements or broader financing details, nor is it a report publication announcement. The correct category is Share Issue/Capital Change (SHA).
2026-05-20 English
Close of Offer - Listing Options 1
Share Issue/Capital Change Classification · 85% confidence The document is an ASX announcement titled “Close of Offer – Listing Options.” It provides details on the listing of options under ASX code “FREO” and confirms no further options were issued. This is clearly a notice of a capital structure change (listing of new equity-linked instruments), fitting the “Share Issue/Capital Change” category.
2026-05-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.